0RDB
Sign in
Oryzon Genomics S.A.
Save
98.49M
Market cap
–
Current P/E
–
Forward P/E
About
Health care
Sector
Medical - Pharmaceuticals
Industry
Oryzon Genomics S. A., a clinical phase biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for patients with cancer and CNS disorders. Its clinical phase compounds include iadademstat (ORY-1001), a selective LSD1 inhibitor that is in Phase II trials for oncology; and vafidemstat (ORY-2001), a CNS-optimized LSD1 inhibitor, which is in Phase II trials for the treatment of CNS and psychiatric diseases.
Similar securities
Based on sector and market capitalization
Report issue